a clinical flow-chart for the “treatment-resistant smoker”
DESCRIPTION
A Clinical Flow-Chart for the “Treatment-Resistant Smoker”. Renee Bittoun. Background. Most smokers want to quit (Fong, 2004) Very few do not (about 6% in Australia) Many/most fail at quit attempts with or without pharmacotherapies (Cohrane Reviews). - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/1.jpg)
A Clinical Flow-Chart for the “Treatment-Resistant Smoker”
Renee Bittoun
![Page 2: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/2.jpg)
Background
• Most smokers want to quit (Fong, 2004)
• Very few do not (about 6% in Australia)
• Many/most fail at quit attempts with or without pharmacotherapies (Cohrane Reviews)
![Page 3: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/3.jpg)
WHO: International Framework Convention on Tobacco Control,
2005The Framework Convention on Tobacco
Control (FCTC): Article 1. Section D.
harm reduction strategies
to improve the health of a population by eliminating or reducing their consumption
of tobacco products
![Page 4: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/4.jpg)
Background to harm-reduction
• Using pharmacotherapies while smoking inhaled toxicants (Fagerstrom,2002)
• Potential gateway to quitting (Fagerstrom, 2005; Hughes, 2005)
• Harm-reduction agenda a softer,
not the “stop smoking or you’ll die” dogma of abrupt quitting (Warner, 2005)
![Page 5: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/5.jpg)
Benefits of using NRT for Harm-reduction and Temporary Abstinence
• Relief of craving and other withdrawal symptoms
• Reduced cigarette consumption and prevention of compensatory smoking
• Smokers may learn that they can manage without tobacco for several hours
motivation to quit
![Page 6: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/6.jpg)
Back ground to combination therapies
• Combination therapies show good outcomes in “hard-to-treat” smokers (Bittoun, 2005)
![Page 7: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/7.jpg)
• A flow chart has been developed for clinicians that directs management of the difficult smoking patient: from the disinterested to the poor responders
• The flow-chart shows increasing therapies as required, using clinical signs and symptoms (withdrawal) to guide treatment choices
![Page 8: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/8.jpg)
![Page 9: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/9.jpg)
Application
• Apply strategies, both NRT and smoking---to mental health/intellectually disabled smokers
• 90% comorbid COPD patients using combination/harm reduction
![Page 10: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/10.jpg)
Some Results
• 16% no pharmacotherapies• 16% oral NRT (gum,lozenge)• 16% on 2 X 21mg patch• 21% on 2 X 21mg patch plus oral NRT• 5% on 3 X 21mg patch• 5% on Bupropion• 1% on Bupropion plus 21mg patch• 20% lost to follow-up
![Page 11: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/11.jpg)
Reconciliation
• Many do not have the “wherewithal” to quit as:- too hard (overwhelming withdrawals) pharmacotherapies too expensive limited understanding of withdrawals• Akrasia (lack of will-power, inability to reconcile
your want/need with your action, loss of control=addictive behaviour) (Aristotle, 4BCE; Heather, 1998; Ainslie, 2001)
• Harm-reduction may be a softer option
![Page 12: A Clinical Flow-Chart for the “Treatment-Resistant Smoker”](https://reader035.vdocument.in/reader035/viewer/2022070406/568141e5550346895dadc49f/html5/thumbnails/12.jpg)
CONCLUSION• Don’t abandon the “hard-to-treat” “can’t quit”
smoker
• Develop a hierarchy of strategies for smokers that begins with permanent cessation using increasing combinations as required but----
• Consider harm-reduction for resistant smokers• ?? Unethical to exclude recommending harm
reduction behaviours to resistant smokers as an alternative to the “Quit or You’ll Die” Dogma.